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D-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) is a Food and Drug Administration (FDA) approved biomaterial that
can form nanosized micelles in aqueous solution. TPGS micelles stand as an interesting system to perform drug delivery as they
can carry lipophilic drugs and overcome P glycoprotein efflux as well. ,erefore, TPGS micelles combined with other copolymers
have been reported in many cancer research studies as a carrier for therapeutic drugs.,eir ability to reach tumoral tissue can also
be exploited to develop imaging agents with diagnostic application. A radiolabeling method with 99mTc for TPGS nanosized
micelles and their biodistribution in a healthy animal model as well as their pharmacokinetics and radiolabeling stability in vivo
was previously reported. ,e aim of this work was to evaluate the performance of this radioactive probe as a diagnostic imaging
agent compared to routinely available SPECTradiopharmaceutical, 99mTc-sestamibi. A small field of view gamma camera was used
for scintigraphy studies using radiolabeled TPGS micelles in two animal models of breast cancer: syngeneic 4T1 murine cell line
(injected in BALB/c mice) and chemically NMU-induced (Sprague-Dawley rats). Ex vivo radioactivity accumulation in organs of
interest was measured by a solid scintillation counter, and a semiquantitative analysis was performed over acquired images as well.
Results showed an absence of tumoral visualization in 4T1 model for both radioactive probes by gamma camera imaging. On the
contrary, NMU-induced tumors had a clear tumor visualization by scintigraphy. A higher tumor/background ratio and more
homogeneous uptake were found for radiolabeled TPGSmicelles compared to 99mTc-sestamibi. In conclusion, 99mTc-radiolabeled
TPGS micelles might be a potential SPECT imaging probe for diagnostic purposes.
1. Introduction
Imaging techniques have become essential diagnostic tools
in clinical practice. Interestingly, small animal imaging has
grown over the last years and positioned as a crucial part of
biomedical preclinical research. It constitutes a noninvasive
modality that provides qualitative and quantitative in-
formation, allowing to explore physiological processes
spatially and temporarily [1]. ,is approach becomes even
more relevant towards imaging probe and even new drug
development, since preclinical results based on imaging
detection should be more readily translatable to clinical area
[1, 2]. Additionally, preclinical imaging agrees with the three
R’s concept in which replacement, reduction, and re-
finement are the requested principles for laboratory animal
use in research [3].
On the other hand, nanomedicine research has grown
exponentially over the past decades and its applications are
of great interest for human health. Unique characteristics of
nanomaterials make them suitable to be exploited in specific
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areas such as therapy and diagnosis of cancer diseases.
Moreover, enhanced permeability and retention effect (EPR,
passive targeting) andmolecularly driven active targeting are
the bedrock in which nanosized systems rely on to address
tumoral tissue [4, 5]. For instance, D-α-tocopheryl poly-
ethylene glycol 1000 succinate (TPGS) is a Food and Drug
Administration (FDA) approved biomaterial that can form
nanosized micelles in aqueous solution [6]. TPGS micelles
stand as an interesting system to perform drug delivery as
they can carry lipophilic drugs and overcome P glycoprotein
efflux as well [7, 8]. ,erefore, TPGS combined with co-
polymers have been reported in many cancer research
studies as a therapeutic drug carrier [6, 9–11]. ,e specific
mechanism by which TPGS-based delivery systems reach
tumoral tissue is not fully understood. However, many re-
ports suggest there is an enhancement of therapeutic effi-
ciency when TPGS is used either as TPGS-drug conjugates
or TPGS with other copolymers. TPGS nanomicelles are
most likely to accumulate rather specifically in tumors by
vasculature fenestrations in angiogenic blood vessels or by
specific targeting as folate, transferrin, or even antibody
exposing TPGS-based drug delivery systems [12–14]. Most
of the approaches are related to therapeutic interventions
but its ability to reach tumoral tissue, possibly by EPR effect
(passive targeting) or specific binding (active targeting), can
also be exploited to develop imaging agents with diagnostic
application.
Breast cancer is the most common cancer among
women, accounting for the highest incidence and mortality
rates worldwide [15]. Early and accurate diagnosis is needed
to improve therapy efficacy and survival rates. Nuclear
medicine imaging is useful in breast cancer at different
instances: diagnosis confirmation, staging, and prediction of
therapeutic response, which are all key factors in treatment
decision. However, 99mTc-sestamibi is the only routinely
available single-photon emission computed tomography
(SPECT) radiopharmaceutical used for mammary scintig-
raphy. In this regard, it is expected that the growing de-
velopment in SPECT equipment and detection technology
parallels with an increasing radioactive probes availability.
In this way, the radiolabeling of TPGSmicelles represents an
interesting strategy to favor imaging probe development.We
have previously reported a radiolabeling method for TPGS
nanosized micelles and their biodistribution in a healthy
animal model as well as their pharmacokinetics and stability
in vivo [16]. ,e aim of this work was to evaluate the
performance of this radioactive probe as a diagnostic im-
aging agent in two distinct breast cancer animal models
compared to a routinely available SPECT radiopharma-
ceutical, 99mTc-sestamibi.
2. Materials and Methods
2.1. Radiolabeling of Radioactive Probes. Radiolabeling of
TPGS micelles (25mg·mL−1) was performed by the direct
method using SnCl2·H2O as reducing agent (7.5 μg/mL) and
37–74 MBq (1–2mCi) of 99mTcO4− (obtained from a 99Mo-
99mTc column generator (BACON SAIC, Argentina), based
on a previous work with slight modifications [16]. Saline
solution (0.9%NaCl) was used as reaction solvent. Radio-
chemical purity (RCP) control was performed as follows:
free 99mTcO4− was measured by paper chromatography
using acetone as mobile phase. Colloidal radioactive im-
purity was assessed by paper chromatography as well (using
saline as mobile phase) and dynamic light scattering. For
comparative purposes, 99mTc-sestamibi was used. It was
synthesized according to the manufacturer’s instructions
(BACON SAIC or Tecnonuclear SA, Argentina). Briefly,
2.2GBq (60mCi) of 99mTcO4− was added to a commercial
freeze-dried kit reaching a final volume of 3mL with saline
solution. Radiochemical purity was assessed as stated in
United States Pharmacopoeia by reverse-phase thin layer
chromatography and by solvent extraction method (chlo-
roform) [17]. 99mTc-sestamibi RCP was above 95% in all
assays.
2.2. TPGS Micelles Size, Zeta Potential, and Morphological
Characterization. 99mTc-radiolabeled TPGS micelles were
analyzed by transmission electronic microscopy (TEM)
(Zeiss EM 109T equipped with a digital camera Gatan
ES1000W, Germany). Samples were placed in a grid and
covered with Formvar film. Finally, they were washed in
distilled water and were dried in a silica gel support.
,e average hydrodynamic diameter and size distribu-
tion of TPGS-radiolabeled micelles and colloidal radioactive
impurity were measured by dynamic light scattering (DLS;
Zetasizer Nano-ZSP, Malvern Instruments, UK) with a He-
Ne laser (633 nm) and a digital correlator ZEN3600. Mea-
surements were performed at a θ� 173° angle. Zeta potential
was measured using the same analyzer, as described else-
where [18]. Samples were previously equilibrated at 25°C,
and results were expressed as the average of three
measurements.
2.3. Cell Culture. 4T1 Breast cancer murine cell line was
obtained from American Type Culture Collection (ATCC®CRL-2539™ BALB/cfC3H strain). Cells were cultured in
RPMI 1640 with fetal bovine serum 10% (FBS), glutamine
0.03%, fungizone 0.001%, and gentamicin 0.004% (Gibco
BRL, EE.UU.) and were kept in an incubator at 37°C in a
humidified atmosphere and 5% CO2.
2.4. 99mTc-Sestamibi and 99mTc-Radiolabeled TPGS Micelles
Uptake in 4T1 Breast Cancer Cell Line. To evaluate the cel-
lular uptake of both radioactive probes, 99mTc-sestamibi and
99mTc-radiolabeled TPGS micelles, cells were grown over 6-
well plastic plates until 70% of confluence was reached. Cells
were then incubated with radioactive probes 0.37–0.74MBq
(10–20 μCi in 100 μL) for 20, 40, 60, and 80minutes in an
incubator (5% CO2, at 37°C). Supernatant was removed and
collected in plastic tubes. Cells were then washed with saline
solution, and samples were kept for further measurements.
Finally, cells were harvested using trypsin (0.25%w/v,
5minutes). Radioactivity from supernatant, washed frac-
tions and cellular fractions was measured in a well-type solid
scintillating counter calibrated with corresponding
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standards (Alfanuclear, ZX, Argentina). Each time point was
assayed in duplicate, and results of three independent ex-
periments are shown as % total activity (added to the culture
medium).
2.5. Experimental Breast Cancer Animal Models. Animal
procedures were in accordance with international recom-
mendations [19, 20], and protocols were approved by Ethical
Committee for the Use and Care of Laboratory Animals of
the School of Pharmacy and Biochemistry (Res D 3686/16).
BALB/c female mice (20–25 g) and female Sprague-
Dawley rats (250–300 g) were purchased from the Di-
vision of Laboratory Animal Production, School of Phar-
macy and Biochemistry, University of Buenos Aires
(Argentina). Animals were kept in stainless steel cages with
food and water ad libitum and 12 h light cycle.
2.5.1. 4T1 Breast Cancer Model in Mice. ,e orthotopic 4T1
breast cancer model was established as described elsewhere
[21]. Briefly, 4T1 cells were collected by centrifugation and
resuspended in 100 μL RPMI-1640. Tumors were induced by
subcutaneous (s.c.) injection of the cells (1× 105) into the
right upper mammary fat pad. Tumor diameters were
measured with a caliper every other day until they reach
4mm to perform imaging studies.
2.5.2. Chemoinduced Breast Cancer Model in Rats.
Mammary tumors were induced in Sprague-Dawley rats by
the carcinogen N-nitroso-N-methyl urea (NMU) as de-
scribed elsewhere [21]. Briefly, tumors were induced by three
intraperitoneal (i.p.) injections (50mg/Kg of body weight) of
NMU (10mg·mL−1 in saline solution) at 50, 80, and 110 days
after rats’ birth. ,e development of breast tumors was
examined by palpation, three times a week, and they were
detected from 90 days after the first administration of NMU.
Tumor size was measured using a caliper every other day
until they reach 8mm to perform imaging studies.
2.6. Imaging Studies and Biological Distribution. Animals
were anesthetized with isoflurane 2%v/v and O2 as carrier. In
vivo uptake of 99mTc-sestamibi or 99mTc-radiolabeled TPGS
micelles was evaluated by intravenous (i.v.) administration
(tail vein) of 0.05–0.1mL (3.7–37MBq or 0.1–1mCi/animal)
to tumor-bearing animals in two sets of imaging studies
performed with each radioactive probe in the same indi-
vidual for rats (N� 3) and two different groups of mice
(N� 8, 4 each group). After 15min of biodistribution
(99mTc-sestamibi) or 12 hours (99mTc-radiolabeled TPGS
micelles), images were acquired with a small field of view
gamma camera (OHIONUCLEAR, software: IM512P,
ALFANUCLEAR, Argentina) equipped with a high-
resolution parallel hole collimator which was used for
ventral imaging. A 256× 256 matrix was used with a 1.25
zoom for mice and 1.5 for rats. Acquisitions were performed
for 15minutes reaching at least 106 counts. Images were
visually analyzed in a band scale to optimize structure
differentiation and identification.
An ex vivo study was performed to evaluate bio-
distribution of radioactive probes in BALB/c mice bearing
4T1 tumors. After imaging, mice were euthanized in a CO2
chamber, and organs of interest were excised, weighted, and
measured in a well-type solid scintillation counter (Alfa-
nuclear, ZX, Argentina) to express results as percentage of
injected dose per gram of tissue (%ID/g).
In the case of NMU-induced tumor bearing rats, a
semiquantitative analysis was performed by creating regions
of interest (ROIs) over acquired images to evaluate radio-
activity in the delimited area.
3. Results
3.1. TPGS Micelles Formation and Size Are Not Altered by
99mTc Radiolabeling. Radiolabeling of TPGS micelles by the
direct method resulted in high yields since less than 5% of
the activity was associated with free pertechnetate
(99mTcO4−) in all experiments. Paper chromatography re-
sults, using saline as a mobile phase, revealed more than 98%
of the activity at the origin. So, colloidal impurities, hy-
drolyzed and reduced 99mTcO4−, were not resolved by this
technique. ,e use of SnCl2 as the reducing agent led to the
formation of a 99mTc colloidal impurity, extensively reported
for 99mTc radiolabeling protocols by the direct method [22].
DLS analysis allowed us to evaluate the presence of that
impurity. A second population was found in the reaction
product sample assessed by DLS (Figure 1(a) (ii) compared
to Figure 1(a) (i)). Population identity was confirmed by
performing an alternative radiolabeling protocol, in absence
of ligand (colloidal formation is highly favored in this re-
action conditions). ,is radiolabeling product was also
analyzed by DLS as it is shown in Figure 1(a) (iii): a colloidal/
particulate structure was found, and it could be assigned to
radioactive impurity by its size (600 nm) as it matches the
second population size found in 99mTc-radiolabeled TPGS
micelles sample. Since colloidal impurity showed a hydro-
dynamic diameter significantly higher than 99mTc-
radiolabeled TPGS micelles, separation by filtration
(0.22 μm methyl cellulose esters, Merck, Germany) was
possible. Filtrated and retained radioactivity was measured
for both radiolabeling protocols: (i) TPGS radiolabeling with
99mTc and (ii) 99mTc radioactive colloid favoring radio-
labeling conditions. Filtration results are shown in Table 1.
Almost half the radioactivity was associated with colloidal
impurity, which was retained in the filter. Moreover, TPGS
nanosized micelles were conserved and retained their ra-
diolabel after filtration, as it can be concluded by results
shown in Figure 1(a) (iv) and Table 1. Finally, 99mTc-
radiolabeled TPGS micelles were characterized regarding
size and morphology by DLS and TEM imaging showing
spherical structures with an average diameter of 9.58 nm and
polydispersion index of 0.09 at 25°C (Figure 1(a) (iv) and
Figure 1(b)). Zeta potential resulted in a −0.217± 1.54mV at
25°C, as well.
3.2. Breast Cancer Animal Model of 4T1 Cell Line Yielded
Negative Imaging Results for 99mTc-Radiolabeled TPGS
Contrast Media & Molecular Imaging 3
Micelles and 99mTc-Sestamibi. Cellular uptake of 99mTc-
radiolabeled TPGS micelles was assessed in 4T1 murine
breast cancer cell line. Accumulation of this radioactive
probe in the cellular fraction was not significant. However,
routinely available and commercial 99mTc-sestamibi was also
evaluated and resulted in less than 1% of the activity
accumulated in 4T1 cells. In vitro results can be seen in
Figure 2(a).
In vivo results revealed the inability of 99mTc-radiolabeled
TPGS micelles to allow tumor localization by gamma camera
imaging in 4T1 breast cancer animal model. Images showed















































































































































Figure 1: (a) Size distribution measured by dynamic light scattering (DLS). (i) TPGS nanomicelles; (ii) TPGS nanomicelles after 99mTc
radiolabeling; (iii) colloidal radioactive impurity; (iv) 99mTc-radiolabeled TPGS micelles after 0.22 μm filtration. (b) Transmission electronic
microscopy photographs of 99mTc-radiolabeled TPGS micelles. (i) Lower magnification; (ii) higher magnification and micelle size labels; (iii)
higher magnification.
Table 1: Activity presence in filtered radiolabeling products (0.22 μm).
TPGS radiolabeling with 99mTc Radiolabeling with
99mTc in colloidal radioactive
impurity favoring conditions
% filtered activity 44± 4 0.7± 0.2
Results are expressed as the percentage of the initial activity that was measured in the filtrated fraction (filtered activity/initial activity∗ 100). ,e mean± SD
of three independent radiolabeling reactions is shown.
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palpable site (shown by green arrows in Figure 2(c)) or any
other organ. Comparatively, no tumoral site was evidenced
by gamma camera imaging using 99mTc-sestamibi either. Ex
vivo biodistribution results confirmed the elevated per-
centages of 99mTc-radiolabeled TPGS micelles in the liver and
spleen predominantly (Figure 2(b)). Kidneys uptake is also
evident ex vivo, although they are not markedly distin-
guished in gamma camera imaging, probably due to su-
perposition in planar acquisition.
99mTc-sestamibi biodistribution was in accordance with
previous reports and extensive radiopharmaceutical use and
knowledge [23, 24]. Heart, kidneys, lungs, bone, and tumor
uptake was higher for 99mTc-sestamibi than for 99mTc-
radiolabeled TPGS micelles. However, specifically for
tumoral site, the difference in radioactive probe accumu-
lation was not enough to be evidenced by acquired images.
Ex vivo results are shown in Figure 2(b).
3.3. 99mTc-Radiolabeled TPGS Micelles Outperform 99mTc-
Sestamibi in Tumoral Visualization by Gamma Camera Im-
aging in Breast Cancer Animal Model Induced by NMU.
Acquired images are shown in Figure 3. 99mTc-sestamibi
biodistribution was consistent with previous results from
our laboratory [24] and others [25, 26]. All palpable tumors
were visualized by gamma camera imaging. Qualitative
analysis revealed a higher tumoral site accumulation for
99mTc-radiolabeled TPGS micelles compared to 99mTc-
sestamibi, resulting in a better imaging signal (increased
counts). Additionally, a semiquantitative analysis was
assayed by drawing regions of interest in tumor and
background areas to calculate tumor/background ratio
shown in Table 2. ,is ratio was at least 3 times higher for
99mTc-radiolabeled TPGS micelles compared with 99mTc-
sestamibi. Interestingly, necrotic areas in tumor core











































































Figure 2: (a) 99mTc-sestamibi and 99mTc-radiolabeled TPGS micelles cellular uptake (4T1 cell line). Results are expressed as the percentage of
activity accumulated in the cellular fraction normalized by 106 cells. (b) 99mTc-sestamibi and 99mTc-radiolabeled TPGS micelles bio-
distribution in a breast cancer animal model developed with 4T1 murine cell line in BALB/c mice. Results are expressed as the percentage of
injected dose in each organ normalized by organ weight (%ID/g). Bars represent mean± SD. (c) Gamma camera imaging of 99mTc-ra-
diolabeled TPGS micelles (12 h after injection) and 99mTc-sestamibi (15min after injection) in a breast cancer animal model developed with
4T1 murine cell line in BALB/c mice. Green arrows indicate the palpable tumoral site. Representative images are shown. Mice outline was
drawn for anatomical references.
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showed homogeneous 99mTc-radiolabeled TPGS micelles
uptake.
4. Discussion
,e radiolabeling of nanosystems, especially with 99mTc,
presents some challenges as the chemistry behind this ra-
dionuclide incorporation is not fully understood. More im-
portantly, radiochemical impurities can appear as a
consequence of the radiolabeling process.,e colloidal nature
of those impurities represents an interference that jeopardizes
result interpretation. Nevertheless, particulate commercial
radiopharmaceuticals do not have a specific radiochemical
assay to evaluate the presence of 99mTc colloid. Additionally,
there is limited information and reports regarding this issue
[27, 28]. In this work we provided, not only a method to
evaluate colloidal impurities but also valuable information in
order to eliminate it from the reaction product. Moreover,
purification by a filtration method using a 0.22 μm filter
is compatible with routine nuclear pharmacy procedures
during radioactive probe synthesis. Size, zeta potential,
and morphology of radiolabeled-TPGS nanomicelles were
also assessed, and though these results may not explain
entirely in vivo results, they are part of the radioactive probe’s
characterization.
,en, pure 99mTc-radiolabeled TPGS micelles were
evaluated for their performance as breast cancer diagnostic
agent compared with a commercially available SPECT ra-
diopharmaceutical, which is routinely used. 99mTc-sestamibi
was firstly introduced in clinical area more than 25 years ago
in the United States (FDA approved in 1990) as a radioactive
probe useful in myocardial perfusion assessment. Simulta-
neously, during the 90s, many publications reported a
preferential uptake of this radiopharmaceutical by cancer
cell lines with respect to normal ones [29–31]. In 2001, a
commercial formulation, with specific use and indication for
breast cancer diagnosis, became available, although it is
currently discontinued. Since then, 99mTc-sestamibi has been
investigated as a diagnostic probe in several types of cancer,
for mammary scintigraphy and parathyroid adenoma im-
aging [32–36]. ,e development of new techniques such as
breast specific gamma imaging (BSGI) has revalued the
usefulness of 99mTc-sestamibi in oncology field [37–40].
Furthermore, the ability of this radiopharmaceutical to
predict or correlate with molecular subtypes of breast cancer
has been very recently explored [41]. ,e evidence described
above indicates that 99mTc-sestamibi is a suitable SPECT
radiopharmaceutical to be used for comparative purposes in
gamma imaging.
In vitro results revealed that there is no 99mTc-
radiolabeled TPGS micelles uptake in 4T1 breast cancer
cell line. In the same way, 4T1 animal model in BALB/c mice
showed negative gamma camera images. ,at is, palpable
tumors were not seen in the acquired images. ,erefore, it
can be concluded that this radioactive probe does not reach
tumoral site neither at a cellular level nor at tumoral in-
terstice. Biodistribution of 99mTc-radiolabeled TPGS micelles












Figure 3: Gamma camera imaging of 99mTc-sestamibi (15min after injection) and 99mTc-radiolabeled TPGS micelles (12 h after injection) in
a breast cancer animal model developed with NMU carcinogen in Sprague-Dawley rats. Each animal was scanned with both radioactive
probes, and representative images from (a) rat#1 and (b) rat#2 are shown. Yellow arrow indicates palpable tumoral site; A, B, and C
represent tumor identification on each rat.
Table 2: Semiquantitative analysis of gamma camera imaging of








A 79.6 26.3 3
B 11.5 2.6 4
C 22.3 3.9 6
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would be responsible for phagocytic hepatic uptake by re-
ticuloendothelial system and could also be a consequence of
interactions with blood elements, such as opsonization,
which could lead to liver accumulation [42, 43].
Since in vivo results have many variables affecting
tumoral uptake such as perfusion, lymphatic drainage, and
blood pool recirculation; among others, there is no way to
identify which ends up determining the net accumulation.
Nevertheless, the absence of gamma camera detection, that
is, a negative image, says enough about 99mTc nanosized
micelles performance as a diagnosis agent in 4T1 breast
cancer animal model. Noticeably, 4T1 in vitro cellular uptake
was higher for 99mTc-sestamibi but it was still a very poor
accumulation (lower than other breast cancer cell lines, such
as human MDA-MB-231 and MCF-7, data not shown). In
this line, commercially available and routinely used 99mTc-
sestamibi rendered negative images in the breast cancer
animal model of 4T1.
On the other hand, very different results were found in
gamma camera imaging of NMU-induced tumor bearing
animals. All tumors from NMU breast cancer animal model
were found to be epithelial neoplasias, particularly invasive
carcinomas. However, each had different histologic type
(data not shown) [44]. ,erefore, for comparative purposes,
we imaged each animal with both radioactive probes.
Noninvasive gamma imaging proved to be useful in this
sense. From a diagnostic perspective, the usefulness and
information provided by imaging preclinical studies are of
utmost importance in imaging probe development. In this
case, both radioactive probes were able to show tumor lo-
calization. However, diagnostic performance was signifi-
cantly different. 99mTc-radiolabeled TPGS micelles had an
enhanced tumor uptake since every tumor was visualized by
gamma camera imaging. Additionally, the tumor/
background ratio in each tumor resulted at least 3 times
higher for 99mTc-radiolabeled TPGS micelles than 99mTc-
sestamibi. Interestingly, one tumor showed a cold core in
99mTc-sestamibi image, which was further assigned to a
necrotic area (data not shown) but a homogeneous uptake
was observed for 99mTc-radiolabeled TPGS micelles image.
,ese results are the baseline to conclude that, with reference
to NMU chemically induced breast cancer animal model,
99mTc-radiolabeled TPGS micelles are superior than 99mTc-
sestamibi as a diagnostic agent for gamma camera imaging.
Further studies are needed to validate 99mTc-radiolabeled
TPGS micelles tumoral uptake in other breast cancer animal
models, test their sensitivity and specificity as a breast cancer
diagnostic agent, and determine the dosimetry associated
with its biodistribution.
5. Conclusions
We conclude that 99mTc-radiolabeled TPGSmicellesmight be
a useful diagnostic agent for gamma camera imaging, pre-
senting proper diagnostic characteristics in NMU-induced
breast cancer animal, even detectable in necrotic areas. It is
important to highlight that the presented radiolabeling
method consists in a procedure that is perfectly compatible
with nuclear medicine service practices.
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